Lung Sound Analysis Provides A Useful Index For Both Airway Narrowing And Airway Inflammation In Patients With Bronchial Asthma

This article was published in the following Dove Press journal:
Journal of Asthma and Allergy

Terufumi Shimoda^{1,2}
Yasushi Obase³
Yukio Nagasaka⁴
Reiko Kishikawa²
Sadahiro Asai¹

¹Department of Allergy, San Remo Rehabilitation Hospital, Sasebo, Japan;
²Department of Allergy, Clinical Research Center, Fukuoka National Hospital, Fukuoka, Japan; ³Department of Respiratory Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan;
⁴Department of Respiratory Medicine, Kyoto Respiratory Center, Otowa Hospital, Kyoto, Japan

Background: The expiration-to-inspiration sound power ratio in a midfrequency range (E/I MF), a parameter of lung sound analysis (LSA), has been reported to be useful as an index of airway inflammation in patients with bronchial asthma. However, the E/I MF reflects airway narrowing caused by airway inflammation, and there is thus concern that it may not be an index of airway eosinophilic inflammation itself.

Methods: A total of 131 patients with bronchial asthma were classified into four groups according to the presence or absence of airway narrowing and airway inflammation to examine whether the E/I MF could serve as an index of airway inflammation.

Results: The E/I MF was significantly higher in patients with a normal forced expiratory volume in one second (FEV₁) and high fractional exhaled nitric oxide (FeNO), those with a low FEV₁ and normal FeNO, and those with a low FEV₁ and high FeNO than in those with a normal FEV₁ and normal FeNO ($p < 0.05$ – 0.01). In particular, the E/I MF was high even in the patients who had no airway narrowing but had airway inflammation ($p < 0.01$). The results of multivariate analysis of factors involved in FeNO in patients with a normal FEV₁ revealed that the E/I MF was an independent factor ($p = 0.0281$).

Conclusion: The E/I MF is a useful index of airway inflammation in the treatment of asthma, regardless of the presence or absence of airway narrowing.

Keywords: airway inflammation, bronchial asthma, E/I MF, FeNO, lung sound analysis

Introduction

Two phenotypes, Th2-high and Th2-low, have been identified in cases of airway inflammation associated with bronchial asthma. The Th2-high phenotype consists of eosinophilic inflammation responsive to inhaled corticosteroid (ICS) treatment, whereas the Th2-low phenotype consists of neutrophilic inflammation resistant to ICS treatment. Duration of these types of airway inflammation brings about airway hyperreactivity and airway narrowing, leading to the airway remodeling that makes the asthma more severe and intractable.^{1–3} In patients with bronchial asthma, the frequency and intensity of auscultatory sounds vary according to variations in the respiratory flow, airway narrowing due to airway injury, and secretions attached to the airway.⁴

We have previously reported that the expiration-to-inspiration sound power ratio in a midfrequency range (E/I MF), a parameter of lung sound analysis (LSA), is a useful index of airway narrowing and airway inflammation in asthma without treatment.^{5–8} We have also reported that the E/I MF increases not only in cases

Correspondence: Terufumi Shimoda
Department of Allergy, San Remo Rehabilitation Hospital, 14848-1 Egamicho, Sasebo 859-3244, Japan
Tel +81-956-58-5900
Fax +81-956-58-5550
Email shimoda2642@e-broad.ne.jp

of eosinophilic inflammation in bronchial asthma but also in cases of neutrophilic inflammation and mixed-type inflammation with them.^{7,8} However, the E/I MF correlates with the forced expiratory volume in one second (FEV₁), which is an index of airway narrowing, as well as with the sputum eosinophil count and fractional exhaled nitric oxide (FeNO), which are known as indices of airway eosinophilic inflammation. Therefore, there is a concern that the E/I MF is an index of airway narrowing resulting from airway inflammation but may not be an index of airway inflammation itself especially in the patients with airway inflammation amended by ICS treatment.

In this study, patients with bronchial asthma who were receiving ICS treatment were divided into four groups by combination of FEV₁ and FeNO to examine whether the E/I MF could be an index of airway inflammation in bronchial asthma.

Methods

Subjects And Study Design

A total of 131 outpatients diagnosed with bronchial asthma from September 2012 to August 2015, who were free of other respiratory disease complications than asthma, such as chronic obstructive pulmonary disease (COPD) or cardiac disease, were subjected. Patients with acute respiratory infection within seven days were excluded. No patients had asthmatic exacerbation, and all patients were undergoing ICS treatment and were nonsmokers or former smokers with less than 10 pack/years. All patients fulfilled the criteria of the Global Initiative for Asthma Guidelines⁹ and reported a history of asthmatic symptoms, including recurrent cough, wheezing or dyspnea, and had positive airway hyperresponsiveness and airway reversibility.

LSA, blood examinations, spirometry, FeNO measurements, and sputum induction and processing were performed in accordance with previously reported procedures.^{5,8,10–12} Anti-asthma drugs were discontinued for at least 24 h prior to examination.

The correlation of the E/I MF with respiratory function, FeNO, or the sputum eosinophil percentage was examined. Regarding airway narrowing, normal (N) was defined when FEV₁/FVC $\geq$ 70% and FEV₁, %pred $\geq$ 80%, otherwise the patient was classified as abnormal airway function (A). Regarding airway eosinophilic inflammation, abnormal FeNO was defined as FeNO $\geq$ 38 ppb, and normal FeNO was defined as FeNO < 38 ppb.¹³ According to the combinations of normal (N) or abnormal (A) FEV₁ and FeNO, the

patients were divided into four groups; FEV₁ (N)-FeNO (N) accounted for 54% (group NN); FEV₁ (N)-FeNO (A), 22% (group NA); FEV₁ (A)-FeNO (N), 16% (group AN); and FEV₁ (A)-FeNO (A), 8% (group AA), and patient characteristics and E/I MF values were compared among these groups.

The study protocol was approved by the ethics committee of Fukuoka National Hospital (protocol no.: 23-14); all participants received verbal and written information about the study before providing their informed consent. The patient consent was written informed consent, and that this study was conducted in accordance with the Declaration of Helsinki.

Measurement Of The FeNO Concentration, Pulmonary Function, Hypersensitivity And Airway Reversibility

Following the guidelines published by the American Thoracic Society (ATS), FeNO was measured using the online single-breath method and a fast-response (0.02 s) chemiluminescence analyzer (Sievers Nitric Oxide Analyzer NOA 280i, GE Analytical Instruments, Boulder, CO, USA).^{11,14} All measurements were obtained using a mouth pressure of 16 cmH₂O, corresponding to an expiratory flow of 50 mL/s. The FeNO concentrations were recorded as the average of 3 values.

Bronchial hypersensitivity was detected by provocative concentration of acetylcholine (Ach) causing a 20% decrease in FEV₁ (PC₂₀) < 8000 mcg/mL and airway reversibility was detected by FEV₁ $\geq$ 12% and increased by 200 mL after inhalation of a bronchodilator. Bronchial hypersensitivity test and airway reversibility test were performed in all patients at any point during the clinical course.

LSA

LSA was performed according to a previously described procedure.^{5,8} The sound recording was performed in a quiet room, but not in a soundproof booth, in the outpatient department. During the patients breathed deeply during the breath sound recording, lung sounds were recorded using a hand-held microphone for $\geq$ 30 seconds over the left lung base. The recording system consisted of an electrostethoscope containing a wide-range audio sensor attached to the inside of a diaphragm (Bio-Sound Sensor BSS-01; Kenz Medico, Saitama, Japan), a signal processing system, and a personal computer. The sensor had a bandpass filter range of 40–2500 Hz and a reliable sound-collecting ability in the 40–2000 Hz range. The

recorded sounds were analyzed by fast Fourier transform using a sound spectrometer software (Easy-LSA; Fukuoka, Japan) and were displayed as a spectrograph.

We defined a frequency range of 200 to 400 Hz as the midfrequency range and determined the inspiration sound power, expiration sound power, and the E/I in this range according to our previous reports.^{5–8}

Statistical Analysis

The characteristics of patients in groups NN, NA, AN and AA were compared by the Wilcoxon/Kruskal–Wallis test, and comparisons by the groups were subsequently performed using the Steel–Dwass method for variables that showed significant differences. The results are shown as medians (25%, 75%). Among the patient characteristics, nominal variables (sex, severity, history of childhood asthma, atopic/nonatopic, ICS amount, concomitant medication with ICS) were compared by Pearson's chi-square test. The correlation of the E/I MF with respiratory function, FeNO, or the sputum eosinophil percentage was determined

using Spearman's rank correlation coefficient. A stepwise procedure for multiple regression analysis was used for multivariate analysis of factors involved in FeNO in the normal FEV1 groups (groups NN and NA). The forward selection method was used for selection from among the following variables: sex, age, body mass index (BMI), amount of smoking, log IgE, and E/I MF. Differences were considered statistically significant at $p < 0.05$. JMP 9 (SAS Institute, Inc., Cary, North Carolina, USA) was used for statistical analysis.

Results

Patient Characteristics And E/I MF Values Of Four Groups Classified By FEV1 And FeNO

A total of 131 patients who had no adventitious lung sounds on auscultation during quiet breathing were classified into four groups (Table 1). Patients in group NN had neither airway narrowing nor airway inflammation, and

Table 1 Patient Characteristics And E/I MF Value When Classified Into 4 Groups By Combination Of FEV1 And FeNO

	NN (n=71)	NA (n=29)	AN (n=21)	AA (n=10)	
FEV1 FeNO	N N	N A	A N	A A	P-value (Pearson)
Male/female, n	18/53	14/15	4/17	4/6	0.074
Age, years	42 (34, 53)	35 (27.5, 60)	53 (33.5, 64.5)	59 (47.5, 67.5)*	
BMI, kg/m ²	22.6 (20.3, 25.5)	23.3 (20.1, 24.6)	20.5 (19.1, 21.9)*(#0.06)	20.5 (18.7, 21.9)	
Severity; step (1,2,3,4)	25/38/8/0	12/12/4/1	3/10/3/5	0/6/3/1	0.0012
Asthma duration, years	2 (0.7, 6)	7 (1, 17)	8 (1, 21.5)*	13.5 (3.3, 18.5)(*0.07)	
History of childhood asthma (no/yes), n	62/9	17/12	17/4	10/0	0.0039
Atopic/non-atopic	37/34	24/5	15/6	4/6	0.0178
Amount of ICS (low/middle/high)	3/67/1	5/22/2	3/13/5	0/9/1	0.0025
Concomitant medicine with ICS (none/montelukast/salmeterol/ combination/others)	26/7/7/31/0	18/1/3/7/0	9/0/3/6/3	4/1/3/1/1	0.0075
IgE (IU/mL)	89 (42, 251)	362 (135, 1283)**\$	157 (47, 244)	187 (87, 436)	
PC20 (µg/mL)	4177 (1250, 7401)	926 (325, 2057)**	754 (356, 2146)**	625 (414, 1472)*	
Blood eosinophils, %	5.1 (2.7, 6.8)	9.3 (6.4, 14.6)**	4.4 (2.3, 8.4)	8.3 (6.0, 11.3)*	
Sputum eosinophils, %	1 (0, 2)	3.5 (1.5, 6)**	5 (1.5, 16.5)**	10.3 (4, 27.1)**	
FEV1/FVC, %	79.9 (76.9, 85.2)	77.9 (75.8, 83.9)	66.8 (60.5, 69.2)	66.3 (63.0, 67.8)	
FEV1,%pred, %	100.9 (94.5, 108.2)	98.7 (93.5, 107.5)	79.1 (71.4, 87.6)	88.4 (76.0, 103.5)(*0.08)	
V50,%pred, %	79.9 (64.7, 97.5)	66.2 (59.8, 80.4)	37.6 (30.7, 48.6)	41.6 (36.2, 46.2)	
V25,%pred, %	57.5 (45.6, 76.6)	54.3 (45.0, 67.2)	28.8 (20.7, 33.3)	31.5 (28.2, 40.6)	
E/I MF	0.30 (0.24, 0.41)	0.43 (0.29, 0.61)*	0.52 (0.34, 0.59) **	0.60 (0.41, 0.73) **	
FeNO, ppb	20.5 (16.4, 24.1)	61.1 (46.4, 86.4)	23.9 (19.7, 28.2)	79.7 (45.5, 87.2)	

Notes: Vs. NN *** $p < 0.001$, ** $p < 0.01$, * $p < 0.05$; Vs. NA #: $p < 0.05$; Vs. AN \$: $p < 0.05$. The data are indicated by median (25%, 75%). FEV1: A (abnormal); FEV1/FVC $< 70\%$ or FEV1, %pred $< 80\%$, N (normal); FEV1/FVC $\geq 70\%$ and FEV1, %pred $\geq 80\%$. FeNO: A (abnormal); FeNO ≥ 38 ppb, N (normal); FeNO < 38 ppb. Severity: step 1/2/3/4; mild intermittent/mild persistent/moderate persistent/severe persistent. Amount of ICS (low/middle/high); low; conversion to beclomethasone dipropionate (BDP) ≤ 400 µg/day, middle; 400–800 µg/day; high; BDP: 800–1600 µg/day, combination; budesonide/formeterol or salmeterol/fluticasone.

their asthma was in good control. In group NA, the patients' serum IgE levels were high, the atopic type was common, and the blood and sputum eosinophil percentages were high. In group AN, patients with a long disease duration was predominant, and the sputum eosinophil percentage was surprisingly high. In group AA, the patient age was relatively high, and the blood and sputum eosinophil percentages were high. Airway hyperreactivity was significantly increased in groups NA, AN, and AA compared with group NN. A moderate ICS dose without concomitant medication was predominant in group NA, whereas a high ICS dose was predominant in group AN.

Figure 1 shows the E/I MF values obtained in the four groups of patients classified according to combinations of FEV₁ and FeNO in an easy-to-understand format; these values are excerpted from Table 1. The E/I MF values in groups NA, AN, and AA were significantly higher than those in group NN (group NN = 0.30 [0.24, 0.41] versus group NA = 0.43 [0.29, 0.61], $p < 0.05$; group AN = 0.52 [0.34, 0.59], $p < 0.01$; and group AA = 0.60 [0.41, 0.73], $p < 0.01$).

Correlation Of The E/I MF With Respiratory Function, FeNO, Or Sputum Eosinophil Percentage

The E/I MF was found to have a significant negative correlation with FEV₁/FVC, FEV₁,%pred, maximal expiratory flow at 50% (V₅₀),%pred, and maximal expiratory flow

at 25% (V₂₅),%pred, which are indices of airway narrowing ($r = -0.199$ to -0.435 , $p = 0.0229$ to $p < 0.0001$). In addition, the E/I MF showed a significant positive correlation with FeNO, which is an index of airway inflammation, and with the sputum eosinophil percentage ($r = -0.264$, $p = 0.0024$; $r = 0.382$, $p < 0.0001$, respectively; Table 2).

Factors Involved In FeNO In Normal FEV1 Groups

When factors involved in FeNO were examined by multivariate analysis in normal FEV1 groups (groups NN and NA), sex (male; t -value = -3.83 , $p = 0.0002$), amount of ex-smoking (t -value = -2.82 , $p = 0.0058$), log IgE (t -value = 3.50 , $p = 0.0007$), and E/I MF (t -value = 2.23 , $p = 0.0281$) were found to be significantly involved (Table 3).

Discussion

In this study, which included patients with bronchial asthma receiving ICS treatment, the E/I MF values were compared among four groups of patients classified according to combinations of FEV₁/FVC, FEV₁,%pred, and FeNO. The results revealed E/I MF values to be significantly higher in patients in whom either the FEV1 or FeNO was abnormal, i.e., those with a normal FEV1 and high FeNO (group NA) and those with a low FEV1 and normal FeNO (group AN), and in patients in whom both the FEV1 and FeNO were abnormal (group AA), than in patients with a normal FEV1 and normal FeNO (group NN).

In particular, the E/I MF was found to be an independent factor by multivariate analysis of factors involved in FeNO in patients with bronchial asthma with FEV₁/FVC $\geq 70\%$ and FEV₁,%pred $\geq 80\%$ who were receiving ICS treatment (groups NN and NA). Therefore, it is speculated that the E/I MF, in addition to FeNO, is a useful index of the ICS-mediated inhibition of airway inflammation in the treatment of bronchial asthma.

Table 2 Correlation Between E/I MF And Respiratory Function, FeNO, Sputum Eosinophils

vs. Variable	Spearman Rank Correlation Coefficient (ρ)	p-Value (Prob> ρ)
FEV ₁ /FVC (%)	-0.369	<0.0001
FEV ₁ ,%pred. (%)	-0.199	0.0229
V ₅₀ ,%pred. (%)	-0.435	<0.0001
V ₂₅ ,%pred. (%)	-0.370	<0.0001
FeNO (ppb)	0.264	0.0024
Sputum eosinophils (%)	0.382	<0.0001

Figure 1 Comparison of E/I MF values in four groups classified by combinations of FEV₁ and FeNO. FEV₁; abnormal (A) cases were defined as FEV₁/FVC $< 70\%$ or FEV₁, %predicted $< 80\%$. Normal (N) cases were defined as FEV₁/FVC $\geq 70\%$ and FEV₁, %predicted $\geq 80\%$. FeNO; abnormal (A) cases were defined as FeNO ≥ 38 ppb, whereas normal (N) cases were defined as FeNO < 38 ppb. * $p < 0.05$, ** $p < 0.01$.

Table 3 Factors Involved In FeNO In FEV1 Normal Groups (group NN And NA) By Multivariate Analysis

	Estimate	SE	t-Value	p-Value	(95% CI)
Sex[F]	-10.04	2.62	-3.83	0.0002	(-15.254,-4.830)
Age (years)	0.21	0.16	1.28	0.2020	(-0.115,0.534)
Ex-smoking (pack-years)	-3.76	1.33	-2.82	0.0058	(-6.412,-1.116)
log IgE	12.16	3.47	3.50	0.0007	(5.267,19.060)
E/I MF	26.82	12.02	2.23	0.0281	(2.945,50.685)

Notes: $R^2=0.336$, analysis of variance <0.001 .

In asthmatic patients, it is believed that FeNO allows assessment of eosinophilic inflammation of the airway.^{15,16} In group NA, the serum IgE level was high, showing increased airway hyperreactivity. In group AN, which included many patients with a history of childhood asthma, increased airway hyperreactivity was found in two forms. In one form, FeNO was normal, but the sputum eosinophil percentage was relatively high, showing the persistence of eosinophilic inflammation. In the other form, noneosinophilic airway inflammation is present, showing the probable involvement of neutrophilic airway inflammation. In group AA, patients of an advanced age were predominant, and airway hyperreactivity was increased. There were significant differences in the ICS amount and types of concomitant medication with ICS among the four groups of patients. Differences in the treatment regimens may have had an influence on airway narrowing and airway inflammation, causing some effects on the E/I MF values. Therefore, it seems possible that the treatment regimen can be altered with reference to the E/I MF, as well as FeNO.

In this study, multivariate analysis showed that male patients tended to be predominant among those who had abnormal FeNO. However, the reason for the predominance of male patients remains unclear. In regard to the influences of sex on asthma control or severity of the disease, some studies have shown that severe cases are more frequent among female patients;^{17,18} in contrast, there have also been reports indicating that respiratory failure is more likely to occur in men¹⁹ and describing little difference in respiratory failure according to sex,^{20,21} making this issue controversial.

In patients with asthma, respiratory function has been used as an index of airway narrowing and FeNO has been used as an index of airway eosinophilic inflammation. The present study suggests that the E/I MF obtained by LSA is useful as an index of both airway narrowing and airway inflammation. A number of previous studies of lung sounds in asthmatic patients have analyzed abnormal sounds and rales obtained on routine auscultation and analyzed lung

sounds during airway narrowing,²²⁻²⁴ but few studies have focused on correlations between the results of LSA and indicators of airway inflammation. In this study, we found that the remaining minimal airway inflammation was detectable by LSA in asthmatic patients who showed normal findings on usual auscultation, normal respiratory function. The E/I MF is a turbulent flow sound energy ratio that includes respiratory cycle elements of air transfer in the airway and serves as an index of obstructive airway narrowing. Therefore, the E/I MF characteristically has good sensitivity, which allows the detection of mild airway narrowing due to slight edema of the bronchial mucosa resulting from airway inflammation in patients with asthma at early onset that is not associated with airway remodeling. Slight airway narrowing cannot be detected by the usual respiratory function test, whereas the E/I MF is capable of detecting them. The main cause of airway narrowing in cases of mild asthma is eosinophilic airway inflammation. However, FeNO does not have sufficient power to detect the severity of eosinophilic airway inflammation in patients with mild asthma. Therefore, the E/I MF is useful not only as an index of airway narrowing but also as an index of mild eosinophilic airway inflammation. In addition, we have previously reported that the E/I MF is useful as an index of neutrophilic inflammation and mixed-type inflammation involving both eosinophils and neutrophils⁸ and it is useful as an index for the localization of airway narrowing and airway inflammation by examining lung sounds at seven sites in the thoracic wall.⁷

There are some limitations in this study, firstly the ICS treatments were introduced in various situations for the patients, and this might influence the levels of airway remodeling which consisted of the irreversible airway narrowing. Secondly, the subject number may be not enough. However, these limitations may not change the utility of the E/I MF, because these variabilities were also included in the multivariate analysis.

In conclusion, the E/I MF, a parameter of LSA, can be used not only to detect remaining airway inflammation

noninvasively in patients who have normal respiratory function but also as an index of airway narrowing in patients with asthma.

Abbreviations

LSA, lung sound analysis; FeNO, fractional exhaled nitric oxide; FEV₁, forced expiratory volume in one second; FVC, forced vital capacity; V₅₀ and V₂₅, maximal expiratory flow at 50% and 25%; E/I LF, the expiration-to-inspiration sound power ratio in a low-frequency range; E/I MF, the expiration-to-inspiration sound power ratio in a midfrequency range; PC₂₀, provocative concentration of acetylcholine causing a 20% decrease in FEV₁; COPD, chronic obstructive pulmonary disease; ICS, inhaled corticosteroid.

Acknowledgments

The authors would like to thank Miss Oda and Miss Kojima for their technical assistance and for performing the statistical analyses.

Author Contributions

TS designed the study, participated in the data analysis and wrote the manuscript. YO assisted in the data analysis. YN assisted in the lung sound analysis. RK assisted in the examinations. SA assisted in the design of the study and revised the manuscript. All authors contributed to data analysis, drafting or revising the article, gave final approval of the version to be published, and agree to be accountable for all aspects of the work.

Funding

This study was supported by Fukuoka National Hospital research funding from 2011 to 2015.

Disclosure

The authors report no conflicts of interest in this work.

References

- Barnes PJ. Therapeutic approaches to asthma-chronic obstructive pulmonary disease overlap syndromes. *J Allergy Clin Immunol*. 2015;136:531–545.
- Banaszak EF, Kory RC, Snider GL. Phonopneumography. *Am Rev Respir Dis*. 1973;107:449–455. doi:10.1164/arrd.1973.107.3.449
- Forgacs P, Nathoo AR, Richardson HD. Breath sounds. *Thorax*. 1971;26:288–295. doi:10.1136/thx.26.3.288
- Shreur HJW, Vanderschoot J, Zwinderman AH, Dijkman JH, Sterk PJ. The effect of methacholine-induced acute airway narrowing on lung sounds in normal and asthmatic subjects. *Eur Respir J*. 1995;8:257–265. doi:10.1183/09031936.95.08020257
- Shimoda T, Obase Y, Nagasaka Y, Nakano H, Kishikawa R, Iwanaga T. Lung sound analysis and airway inflammation in bronchial asthma. *J Allergy Clin Immunol Pract*. 2016;4:505–511. doi:10.1016/j.jaip.2016.02.001
- Shimoda T, Obase Y, Nagasaka Y, Nakano H, Kishikawa R, Iwanaga T. Lung sound analysis is useful for monitoring therapy in patients with bronchial asthma. *J Investig Allergol Clin Immunol*. 2017;27:246–251. doi:10.18176/jiaci.0132
- Shimoda T, Obase Y, Nagasaka Y, et al. Lung sound analysis helps localize airway inflammation in patients with bronchial asthma. *J Asthma Allergy*. 2017;10:99–108. doi:10.2147/JAA.S125938
- Shimoda T, Obase Y, Nagasaka Y, Asai S. Phenotype classification using the combination of lung sound analysis and fractional exhaled nitric oxide for evaluating asthma treatment. *Allergol Int*. 2018;67:253–258. doi:10.1016/j.alit.2017.09.004
- Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention. NHLBI/WHO Report. Bethesda National Institutes of Health, National Heart, Lung and Blood Institute. NIH Publication: 02e3659; 2017. Available from: www.ginasthma.org. Accessed October 01, 2019.
- Metso T, Ryttilä P, Peterson C, Haahtela T. Granulocyte markers in induced sputum in patients with respiratory disorders and healthy persons obtained by two sputum-processing methods. *Respir Med*. 2001;95:48–55. doi:10.1053/rmed.2000.0970
- Silkoff PE. Recommendations for standardized procedures for the online and offline measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide in adults and children. *Am J Respir Crit Care Med*. 1999;160:2104–2117. doi:10.1164/ajrccm.160.6.ats8-99
- Tsurikisawa N, Oshikata C, Tsuburai T, et al. Bronchial hyperresponsiveness to histamine correlates with airway remodelling in adults with asthma. *Respir Med*. 2010;104:1271–1277. doi:10.1016/j.rmed.2010.03.026
- Sato S, Saito J, Sato Y, et al. Clinical usefulness of fractional exhaled nitric oxide for diagnosing prolonged cough. *Respir Med*. 2008;102:1452–1459. doi:10.1016/j.rmed.2008.04.018
- Shimoda T, Nagasaka Y, Obase Y, Kishikawa R, Iwanaga T. Prediction of airway inflammation in patients with asymptomatic asthma by using lung sound analysis. *J Allergy Clin Immunol Pract*. 2014;2:727–732. doi:10.1016/j.jaip.2014.06.017
- Hamid Q, Springall DR, Riveros-Moreno V, et al. Induction of nitric oxide synthase in asthma. *Lancet*. 1993;342:1510–1513. doi:10.1016/s0140-6736(05)80083-2
- Payne DN, Adcock IM, Wilson NM, Oates T, Scallan M, Bush A. Relationship between exhaled nitric oxide and mucosal eosinophilic inflammation in children with difficult asthma, after treatment with oral prednisolone. *Am J Respir Crit Care Med*. 2001;164:1376–1381. doi:10.1164/ajrccm.164.8.2101145
- Badiola C, Badiella L, Plaza V, Prieto L, Villa JR, Cimas E. Women, patients with severe asthma, and patients attended by primary care physicians, are at higher risk of suffering from poorly controlled asthma. *Prim Care Respir J*. 2009;18:294–299. doi:10.4104/pcrj.2009.00027
- Belloch A, Perpina M, Martinez-Moragon E, de Diego A, Martinez-Frances M. Gender differences in health-related quality of life among patients with asthma. *J Asthma*. 2003;40:945–953. doi:10.1081/jas-120024595
- Zein JG, Udeh BL, Teague WG, et al. Impact of age and sex on outcomes and hospital cost of acute asthma in the United States, 2011–2012. *PLoS One*. 2016;11:e0157301. doi:10.1371/journal.pone.0157301
- Dursun AB, Kurt OK, Bayiz H, Ozkan E, Cakaloglu A, Karasoy D. Does gender affect asthma control in adult asthmatics? *Chron Respir Dis*. 2014;11:83–87. doi:10.1177/1479972314527468
- Raherison C, Janson C, Jarvis D, et al. Evaluation of asthma severity in a cohort of young adults: is there any gender difference? *PLoS One*. 2009;4:e7146. doi:10.1371/journal.pone.0007146

22. Nagasaka Y. Lung sounds in bronchial asthma. *Allergol Int.* 2012;61:353–363. doi:10.2332/allergolint.12-RAI-0449
23. Anderson K, Aitken S, Carter R, Macleod JES, Moran F. Variation of breath sound and airway caliber induced by histamine challenge. *Am Rev Respir Dis.* 1990;141:1147–1150. doi:10.1164/ajrccm/141.5_Pt_1.1147
24. Habukawa H, Murakami K, Mochizuki M, et al. Changes in the highest frequency of breath sounds without wheezing during methacholine inhalation challenge in children. *Respirology.* 2010;5:485–490. doi:10.1111/j.1440-1843.2010.01706.x

Journal of Asthma and Allergy

Dovepress

Publish your work in this journal

The Journal of Asthma and Allergy is an international, peer-reviewed open-access journal publishing original research, reports, editorials and commentaries on the following topics: Asthma; Pulmonary physiology; Asthma related clinical health; Clinical immunology and the immunological basis of disease; Pharmacological interventions and

new therapies. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/journal-of-asthma-and-allergy-journal>